Keywords: Amgen, Prolia, FDA, USA, Osteoporosis

Another boost for Amgen as US FDA approves injectable osteoporosis drug Prolia, with peak sales expectations of as much as $6 billion

Article | 02 June 2010

Print This

There was good news for US biotechnology major Amgen yesterday, when the Food and Drug Administration approved the firm’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in